Form 8-K - Current report:
SEC Accession No. 0001104659-25-047013
Filing Date
2025-05-12
Accepted
2025-05-12 07:15:26
Documents
14
Period of Report
2025-05-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2514754d1_8k.htm   iXBRL 8-K 27305
2 EXHIBIT 99.1 tm2514754d1_ex99-1.htm EX-99.1 56304
  Complete submission text file 0001104659-25-047013.txt   267989

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA btai-20250512.xsd EX-101.SCH 3047
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE btai-20250512_lab.xml EX-101.LAB 34239
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE btai-20250512_pre.xml EX-101.PRE 22380
16 EXTRACTED XBRL INSTANCE DOCUMENT tm2514754d1_8k_htm.xml XML 3562
Mailing Address 555 LONG WHARF DRIVE NEW HAVEN CT 06511
Business Address 555 LONG WHARF DRIVE NEW HAVEN CT 06511 203-643-8060
BioXcel Therapeutics, Inc. (Filer) CIK: 0001720893 (see all company filings)

EIN.: 821386754 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38410 | Film No.: 25932574
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)